[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd22-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD22 Gene",24,21,[8,16,23,29,35,42,48,54,60,67,73,78,84,90,96,101,107,113,119,125,131,137,143,150],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02981628","Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",[12],"Phase 2","RECRUITING","2026-08-03T00:52:47.662427Z","2026-07-05T05:32:16.771394Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03150693","Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia",[20],"Phase 3","2026-08-26T02:16:51.982021Z","2026-07-05T05:32:16.770812Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",[12],"2026-08-26T02:18:33.598205Z","2026-06-06T00:48:49.516454Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT02877303","Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.482656Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[39],"Phase 1","2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.029325Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06559189","CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",[39],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:28.501492Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05010564","Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)",[39],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.287884Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06863259","Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL",[39],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.191020Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT05674175","Co-administration of CART22-65s and huCART19 for B-ALL",[64],"Phase 1\u002FPhase 2","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.600390Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",[12],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.390966Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":52,"content_modified":77},"NCT04815356","Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed\u002FRefractory Hairy Cell Leukemia and Variant",[39],"2026-05-05T02:43:27.133485Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT03739814","Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.037393Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[39],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:26.924544Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT04150497","Phase 1\u002F2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",[64],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.923457Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":88,"content_modified":100},"NCT03104491","Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia",[64],"2026-05-05T02:35:31.864785Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07109219","Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia",[64],"2026-08-26T02:17:21.315591Z","2026-04-29T02:57:57.110500Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT03959085","Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",[20],"2026-08-26T02:18:17.950264Z","2026-07-05T03:45:20.447682Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[39],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[64],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[39],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[39],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":138,"title":139,"phases":140,"status":141,"updated_at":65,"content_modified":142},"NCT07313852","A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia",[64],"NOT_YET_RECRUITING","2026-05-05T02:43:26.936493Z",{"nct_id":144,"title":145,"phases":146,"status":147,"updated_at":148,"content_modified":149},"NCT03226704","Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:13.549512Z","2026-06-16T05:54:07.964568Z",{"nct_id":151,"title":152,"phases":153,"status":147,"updated_at":154,"content_modified":155},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[39],"2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z"]